BeiGene Ltd ADR diskutieren
BeiGene Ltd ADR
WKN: A1437N / Symbol: BGNE / Name: BeiGene / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
224,00 €
4,67 %
BeiGene, Ltd. (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $350.00 price target on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $297.00 to $300.00. They now have an "overweight" rating on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Morgan Stanley from $321.00 to $319.00. They now have an "overweight" rating on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $259.00 price target on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Citigroup Inc. from $290.00 to $285.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $185.00 price target on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Guggenheim from $350.00 to $345.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $184.00 to $186.00. They now have an "overweight" rating on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $235.00 to $236.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $236.00 to $254.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at Citigroup Inc. from $269.00 to $288.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $194.00 to $200.00. They now have an "overweight" rating on the stock.
Ratings data for BGNE provided by MarketBeat
Neueste Beiträge
StockNews_com in Ampio Pharmaceuticals Inc. diskutieren